natgillin/translations-raw huggingface dataset:
TruScient used in concentrations or amounts greater than those recommended is associated with excessive bone formation and increased generation of fluid-filled void spaces within the induced bone.
Uporaba zdravila TruScient v koncentracijah ali količinah, večjih od priporočenih, je povezana s prevelikim nastajanjem kostnine in povečanim nastankom s tekočino napolnjenih prostorov v zdravljeni kosti.
When injected intravenously, the terminal half-life of dibotermin alfa was 16 minutes in rats.
Po intravenski aplikaciji je bila končna razpolovna doba dibotermina alfa pri podganah 16 minut.
Place the prepared sponge so that it bridges the fracture and makes good contact with the major proximal and distal fracture fragments.
Pripravljeno gobico namestite tako, da bo premostila mesto zloma in bo v tesnem stiku z večjimi proksimalnimi in distalnimi fragmenti.
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisi.
In case of accidental spillage onto skin and eyes rinse off immediately.
V primeru nenamernega razlitja po koži ali v oči nemudoma sperite.
The ability of TruScient to support bone remodeling may be responsible for the biological and biomechanical integration of the new bone induced by TruScient with that of the surrounding bone.
Sposobnost zdravila TruScient, da podpira preoblikovanje kosti, je verjetno vzrok za biološko in biomehansko integracijo nove kosti, nastale po indukciji z zdravilom TruScient, z okolnim kostnim tkivom.
Although no clear association with clinical outcome or undesirable effects could be observed in clinical and safety studies, the possibility of developing neutralising antibodies or hypersensitivity-type reactions cannot be excluded.
Čeprav v kliničnih študijah in študijah varnosti niso opazili jasne povezave s kliničnim izidom ali pojavom neželenih učinkov, pa možnosti nastanka nevtralizirajočih protiteles ali preobčutljivostnih reakcij ni mogoče izključiti.
The safety, including potential immune responses and effectiveness of repeat TruScient administration have not been evaluated in dogs.
Varnosti vključno z morebitnimi imunskimi reakcijami in učinkovitosti pri ponavljajočem se dajanju zdravila pri psih niso ocenili.
Biomechanical data suggest these voids had little influence on the biomechanical properties of the induced bone or its integration with the abutting cortices.
Biomehanični podatki kažejo na to, da imajo ti prostori le majhen vpliv na biomehanične lastnosti inducirane kostnine ali njeno integracijo z ujemajočimi se korteksi.
This medicinal product should only be used in breeding, pregnant and lactating dogs following a risk/benefit assessment by the responsible veterinarian.
Pri vzrejnih psih, psicah v obdobju brejosti in laktacije uprabite zdravilo le po predhodni oceni koristi/tveganja odgovornega veterinarja.
Both rhBMP-2 and bovine Type I collagen can elicit an immune response in dogs.
Tako rhBMP-2 kot goveji kolagen tipa I lahko sprožita imunski odgovor pri psih.
The bone formation process develops from the outside of the prepared sponge towards the center until the entire prepared sponge is replaced by trabecular bone.
Proces nastajanja kosti se razvija v smeri od zunanjih delov implantata proti sredini, dokler trabekularna kost ne nadomesti celotnega implantata.
TruScient does not provide mechanical stability and should not be used to fill space in the presence of compressive forces.
TruScient ne zagotavlja mehanske stabilnosti in se ga ne sme uporabiti za zapolnitev prostora pri delovanju kompresijskih sil.
The safety of the veterinary medicinal product has not been established during breeding, pregnancy and lactation.
Varnost zdravila med parjenjem, v obdobju brejosti in laktacije ni bila ugotovljena.
1 vial (solvent)
1 viala (vehikel)
For accurate dosing ensure there are no suspended air bubbles in the transfer volumes.
Za natančno odmerjanje zagotovite, da v količinah, ki jih prenašate, ni suspendiranih zračnih mehurčkov.
In animal studies (rats) using radiolabelled dibotermin alfa on absorbable collagen sponge, the mean residence time at the site of implantation was 4-8 days.
V študijah na živalih (podganah), kjer so uporabili zdravilo TruScient, ki je vsebovalo radioaktivno označeni dibotermin alfa na vpojni kolagenski gobi, je bil povprečni čas zadrževanja na mestu implantacije 4-8 dni.
In order to avoid excessive postoperative swelling, use only the amount of prepared TruScient sponge needed to achieve coverage of accessible fracture lines and defects (less than one to up to two prepared sponges).
Da bi preprečili povečano postoperativno otekanje, uporabite najmanjšo količino pripravljene TruScient gobice, potrebne za prekritje dostopnih prelomnih linij in defektov (manj kot eno do dve pripravljeni gobici).
Treatment of diaphyseal fractures as an adjunct to standard surgical care using open fracture reduction in dogs.
Zdravljenje diafiznih zlomov kot dodatek k standardni oskrbi z uporabo odprte redukcije zloma pri psih.
TruScient is active at the site of implantation.
Zdravilo TruScient deluje na mestu implantacije.
The efficacy and safety of the veterinary medicinal product for the treatment of diaphyseal fractures was evaluated in a randomised, controlled, multicenter clinical field study involving dogs randomised to treatment with the veterinary medicinal product plus Standard Of Care (SOC) [n=84] or SOC [n=42] alone.
Učinkovitost in varnost zdravila za zdravljenje diafiznih zlomov so ocenjevali v randomizirani, kontrolirani, multicentrični klinični študiji na terenu, pri kateri so pse naključno razporedili v skupiniena je prejela zdravilo ter standardne postopke oskrbe (Standard Of Care - SOC) [n=84], druga pa samo standardne postopke oskrbe [n=42].
Use only the amount of prepared sponge needed to achieve coverage of accessible fracture lines and defects (less than one up to two prepared sponges).
Uporabite samo toliko pripravljene gobice kot je potrebujete za pokritje dostopnih prelomnih linij in defektov (manj kot eno do dve pripravljeni gobici).
Swirl the vial gently to aid reconstitution.
Vialo previdno obračajte, da pospešite rekonstitucijo.
If only a portion of a prepared sponge is required, first prepare the entire package (following steps 1 - 9 above), then cut or fold the prepared sponge as needed prior to implantation.
Če potrebujete le del pripravljene gobice, morate najprej pripraviti celotno pakiranje zdravila (po zgoraj opisanem postopku, točke od 1-9), gobico nato razrežete ali zvijete tik pred implantacijo.
In the case of dogs receiving concentrations or amounts greater than those recommended, treatment of adverse effects, where required, should be symptomatic.
V primeru, da je pes prejel zdravilo v koncentraciji ali količini, večji od priporočene, in je potrebno zdraviti neželene učinke, uporabite simptomatsko zdravljenje.
BMP-2 antibody response to TruScient was evaluated in 133 dogs receiving surgery for diaphyseal fractures stabilised with internal fixation.
Nastanek protiteles proti BMP-2 zaradi uporabe zdravila TruScient so ocenili pri 133 psih, pri katerih so z operacijo diafizni zlom stabilizirali z interno fiksacijo.
The amount of prepared sponge placed is determined by the fracture anatomy and the ability to close the wound with minimal compression of the sponge.
Količino pripravljene gobice, ki jo potrebujete, določite glede na anatomijo zloma in možnostjo zaprtja rane s kar najmanjšo kompresijo na implantat.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGIH SNOVI
No studies have been performed in dogs with known autoimmune diseases.
Študij pri psih z znano avtoimuno boleznijo niso izvedli.
This self-limitation is likely due to the loss of dibotermin alfa from the application site, as well as the presence of BMP inhibitors in the surrounding tissues.
To samoomejevalno sposobnost gre verjetno pripisati izgubi dibotermina alfa z mesta implantacije, pa tudi prisotnosti inhibitorjev proteina za morfogenezo kosti (BMP - Bone Morphogenetic Protein) v okolnem tkivu.
Sodium hydroxide (pH adjustment agent) Hydrochloric acid (pH adjustment agent)
Natrijev hidroksid (za korekcijo pH) Klorovodikova kislina (za korekcijo pH)
Shelf life of the veterinary medicinal product as packaged for sale: 2 years Shelf life in the vial after reconstitution according to directions: 3 hours Discard any unused veterinary medicinal product.
Rok uporabnosti zdravila v pakiranju za prodajo: 2 leti Rok uporabnosti po rekonstituciji v skladu z navodili: 3 ure Zavrzite neuporabljeno zdravilo.
Do not refrigerate.
Zdravilo ne sme zmrzniti.
Observed clinical signs were listed as adverse reactions for TruScient when they exceeded in intensity and/or duration of what would be considered normal for fracture healing after Standard of Care (SOC).
Opaženi klinični znaki so bili uvrščeni med neželene učinke zdravila TruScient, če je bila njihova intenzivnost in/ali trajanje večja kot pri znakih, ki spremljajo normalno zdravljenje zloma kosti v skladu s standardom zdravljenja (Standard of Care - SOC).
The results demonstrated that TruScient was effective in reducing the time to radiographic fracture union when added to SOC compared to treatment with SOC alone regardless of fracture type (open or closed).
Rezultati so pokazali, da je bil TruScient v kombinaciji s standardnimi postopki oskrbe učinkovit pri skrajšanju časa do radiografsko potrjene zacelitve kosti v primerjavi s samimi standardnimi postopki oskrbe, ne glede na vrsto zloma (odprt, zaprt).
No studies have been performed in dogs with metabolic bone diseases.
Študij pri psih s presnovnimi boleznimi kosti niso izvedli.
10 ml Do not use more than 3.2 ml for reconstitution
10 ml Za rekonstitucijo ne uporabite več kot 3,2 ml.
Two sterile sponges 2.5 x 5 cm in a polyvinyl chloride (PVC) blister package sealed with a Tyvek lid.
Dve sterilni gobi, 2,5 x 5 cm v polivinilkloridnem (PVC) pretisnem omotu, neprodušno zaprtem s pokrovom iz Tyveka
Remodeling of the surrounding trabecular bone occurs in a manner that is consistent with the biomechanical forces placed on it.
Preoblikovanje okolnega trabekularnega kostnega tkiva poteka v skladu z biomehanskimi silami, ki delujejo na to tkivo.
Excessive bone and fluid filled cysts remodel into normal bone over time.
Odvečna kostnina in s tekočino napolnjene ciste se s časom spremnijo v normalno kostnino.
The differentiated cells form trabecular bone as the sponge is degraded, with vascular invasion evident at the same time.
Diferencirane celice ob razpadanju gobice tvorijo trabekularno kostno tkivo, sočasno pa je vidna vaskularna invazija.
Kit for implant
Komplet za implantacijo
Prepare sponges at least 15 minutes prior to use and use within 2 hours of wetting the sponges.
Gobice pripravite vsaj 15 minut pred uporabo in jih uporabite v 2 urah po navlažitvi.
As dibotermin alfa (rhBMP-2) is a protein and has not been identified in the general circulation, it is an unlikely candidate for pharmacokinetic drug-drug interactions.
Ker je dibotermin alfa protein, ki ga v cirkulaciji niso našli, ni verjetno, da bi lahko bil vpleten v farmakokinetične interakcije z drugimi zdravili.
Two sponges made of Bovine Type I collagen.
Dve gobici iz govejega kolagena tipa I.
1 vial (lyophilisate)
1 viala (liofilizat)
Failure to follow the instructions may compromise the safety and effectiveness of the medicinal product.
Neupoštevanje navodil lahko ogrozi varnost in učinkovitost zdravila.
Cut or fold the prepared sponge as needed prior to placement.
Gobico prerežite ali zvijte kot je potrebno, preden jo namestite.
During placement, use forceps to handle the prepared sponge to avoid excessive fluid loss.
Med nameščanjem gobice na ustrezno mesto uporabite forceps, da bi preprečili preveliko iztekanje tekočine.
Bone plates should not be covered with the prepared sponge in order to facilitate plate removal if needed following fracture healing.
Ploščice ne smete prekriti z gobico, da se omogoči morebitna odstranitev ploščice, če bi bilo to potrebno po zaključenem zdravljenju.
TruScient should be used by an appropriately qualified veterinarian.
TruScient sme uporabljati le primerno usposobljen doktor veterinarske medicine.
Date of first authorisation: 14/12/2011 Date of last renewal:
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 14/12/2011
EXP {month/year} Discard the remaining solvent after reconstitution.
EXP {mesec/leto} Po rekonstituciji zavrzite preostanek vehikla.
Shelf life in the vial after reconstitution: 3 hours Discard any unused veterinary medicinal product.
Rok uporabnosti po rekonstituciji: 3 ure Zavrzite neuporabljeno zdravilo.
Name and address of the manufacturer of the biological active substance
Ime in naslov izdelovalca(izdelovalcev) biološke zdravilne učinkovine (zdravilnih učinkovin).
TruScient 0.66 mg kit for implant for dogs
TruScient 0,66 mg komplet za implantacijo za pse
Slowly inject the 3.2 ml of solvent into the lyophilisate vial (see Figure 1) to achieve a 0.2 mg/ml solution of rhBMP-2.
Počasi vbrizgajte 3,2 ml vehikla v vialo z liofilizatom (glejte Sliko 1), da dobite 0,2 mg/ml raztopino rhBMP-2
Using sterile technique, transfer the two 3 ml syringes with needles and the sponges inner package into the sterile field.
Z uporabo sterilne tehnike prenesite dve 3-ml brizgi z iglama in gobici v stični ovojnini v sterilno območje.
TruScient should not be mixed with other agents.
Zdravila TruScient ne smete mešati z drugimi zdravili.
Sponge: Bovine Type I collagen
Goba: Goveji kolagen tipa I
Preclinical studies have suggested that bone formation initiated by TruScient is a self-limiting process, forming a well-defined volume of bone.
Na osnovi predkliničnih študij lahko sklepamo, da je nastajanje kostnega tkiva, ki ga sproži zdravilo TruScient, proces, ki se sam od sebe zaustavi, ko se razvije natančno opredeljen volumen kostnega tkiva.
Very common (more than 1 in 10 animals) Mild to moderate Lameness Firm swelling within the first 3 weeks postoperatively which recedes gradually over several months Soft swelling which recedes within 3 weeks
Zelo pogosti (pojavijo se pri 1 od 10 živali) Blagi do zmerni šepanje čvrsta oteklina do 3 tedne po operaciji, ki postopma izgine v nekaj mesecih mehka oteklina, ki izgine v treh tednih
While there was a treatment-related reduction in time to radiographic fracture union, there was no difference over time between the TruScient treated group and the control group for the individual clinical parameters, lameness and pain, or for an overall score based on clinical signs of fracture healing.
Čeprav je bilo dokazano, da zdravljenje zmanjša čas do radiografsko potrjene zacelitve kosti, pa glede posameznih kliničnih parametrov, šepanja in bolečine oziroma skupne ocene, ki je temeljila na kliničnih znakih celjenja kosti, sčasoma ni bilo razlike med skupino, ki je prejela TruScient in kontrolno skupino.
The incidence of antibody titres in treated dogs under field conditions is low and the puppies will have no or very limited exposure to anti-BMP-2 antibodies due to the potential for limited transfer across the placenta in dogs.
Incidenca titrov protiteles pri zdravljenih psih na terenu je nizka, zaradi morebitnega omejenega prenosa protiteles skozi placento pri psih, mladiči protitelesom anti-BMP-2 ne bodo izpostavljeni, oziroma bodo izpostavljeni v zelo omejenem obsegu.
TruScient 0.66 mg kit for implant for dogs dibotermin alfa (rhBMP-2)
TruScient 0,66 mg komplet za implantacijo za pse dibotermin alfa (rhBMP-2)
Long-bone fracture and soft-tissue management procedures should be based on standard practice, including control of infection.
Za oskrbo zlomov dolgih kosti in poškodb mehkih tkiv uporabite standardne postopke, vključno z obvladovanjem okužb.
The following adverse reactions have been observed in a field study in dogs:
V študijah pri psih na terenu so opazili naslednje neželene učinke:
Dibotermin alfa (rhBMP-2) is an osteoinductive protein that results in the induction of new bone tissue at the site of implantation.
Dibotermin alfa je osteo-induktiven protein, ki spodbuja nastajanje novega kostnega tkiva na mestu implantacije.
One vial of lyophilisate contains:
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena viala z liofilizatom vsebuje:
This veterinary medicinal product should be used by an appropriately qualified veterinarian.
Posebni previdnostni ukrepi za uporabo pri živalih To zdravilo za uporabo v veterinarski medicini sme uporabljati samo ustrezno usposobljen doktor veterinarske medicine.
Using aseptic transfer technique and for each 3 ml syringe with needle, withdraw 1.4 ml from the reconstituted vial of dibotermin alfa (rhBMP-2) in the non-sterile field.
Z uporabo aseptične tehnike v vsako od 3-ml brizg potegnite 1,4 ml iz viale z rekonstituirano raztopino dibotermina alfa (rhBMP-2) v nesterilnem območju.
The following adverse reactions have been observed in laboratory studies in dogs: o Heterotopic ossification of the surrounding tissues o Exuberant bone formation at the site of placement and ectopic bone formation o Excessive bone and fluid filled cysts that remodel into normal bone over time o Increased swelling at the site of placement has been observed by 2-3 weeks post surgery.
V laboratorijskih študijah pri psih so opazili naslednje neželene učinke: - heterotopična osifikacija okolnih tkiv - bohotenje kosti na mestu implantacije in ektopično nastajanje kostnine - povečan nastanek kostnih cist in cist, napolnjenih s tekočino, ki se s časom spremenijo v normalno kostnino - močnejšo oteklino na mestu implantacije so opazili 2-3 tedne po operaciji; otekline so posledica lokalne proliferacije mezenhima, ki zori v novo kostnino, kar je v skladu s farmakološkim delovanjem rhBMP-2.
A. Reconstitute dibotermin alfa (rhBMP-2) in a non-sterile field: 1.
A. Rekonstitucija dibotermina alfa (rhBMP-2) v nesterilnem območju: 1.
If a surgical drain is required, place the drain at least one layer superficial to or remote from the prepared sponge.
Če je potrebna kirurška drenaža, namestite dren eno plast nad mestom implantacije ali daleč stran od mesta implantacije.
Do not use in dogs with a known hypersensitivity to the active substance or to any of the excipients.
Ne uporabite v primeru preobčutljivosti na zdravilno učinkovino ali na katero koli pomožno snov.
Figure 1: Reconstitution of dibotermin alfa (rhBMP-2)
Slika 1: Rekonstitucija dibotermina alfa (rhBMP-2)
D. After Placement
D. Po implantaciji
Peel open the inner package of sponges and leave them in the tray.
Odprite stično ovojnino gobic in ju pustite na pladnju.
LYOPHILISATE VIAL LABEL
NALEPKA ZA VIALO Z VEHIKLOM
Use within 2 hours of wetting the sponges.
Uporabite v 2 urah po pripravi.
Read the instructions below each time the veterinary medicinal product is used.
Pred vsako uporabo zdravila preberite spodnja navodila.
Uncommon (more than 1 but less than 10 animals in 1000 animals) Mild to moderate Exuberant bony callus associated with persistent (>10 weeks) moderate soft tissue swelling and excessive licking of the incision area.
Občasni (pojavijo se pri več kot 1 živali, vendar pri manj kot 10 od 1000 živali ) Blagi do zmerni povečam kostni kalus ter stalna (več kot 10 tednov) zmerna oteklina mehkega tkiva ter močno lizanje območja rane
In the absence of compatibility studies, this veterinary medicinal product must be reconstituted only with the solvents provided and should not be mixed with other solvents or other veterinary medicinal products.
Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili za uporabo v veterinarski medicini, razen z vehiklom, ki je priložen za uporabo s tem zdravilom.
Using the 6 ml syringe and needle, withdraw 3.2 ml of solvent (more solvent is supplied than is needed).
Z uporabo 6 ml-brizge in igle v brizgo potegnite 3,2 ml vehikla (v viali je večja količina vehikla kot je potrebno).
The dibotermin alfa (rhBMP-2) is reconstituted to 0.2 mg/ml solution and then distributed uniformly across both sponges.
Dibotermin alfa (rhBMP-2) rekonstituirajte z 0,2 mg/ml raztopine in nato nastalo raztopino enakomerno nanesite na obe gobici.
Directions: Using aseptic technique, follow the directions below to reconstitute dibotermin alfa (rhBMP-2) for application to the sponges.
Navodila: Z uporabo aseptične tehnike sledite spodnjim navodilom za rekonstitucijo dibotermina alfa (rhBMP-2) za nanašanje na gobici.
2 absorbable collagen sponges 2 sterile 3 ml disposable syringes with needles 1 sterile 6 ml disposable syringe with needle
2 sterilni 3-ml brizgi za enkratno uporabo z iglama 1 sterilna 6-ml brizga za enkratno uporabo z iglo
Using aseptic technique, follow the directions below to reconstitute dibotermin alfa (rhBMP-2) for application to the sponges.
Z uporabo aseptične tehnike sledite spodnjim navodilom za rekonstitucijo dibotermina alfa (rhBMP-2) za nanašanje na gobici.
10 ml Type I glass vial with a chlorobutyl elastomeric closure sealed with an aluminum flipoff seal and plastic cap.
10-ml viala is stekla tipa I z zamaškom iz klorobutilnega elstomera, neprodušno zaprta z aluminijasto zaščitno zaporko in plastičnim pokrovčkom
Failure to follow the TruScient instructions for preparation and use may compromise safety and effectiveness.
Neupoštevanje navodil za pripravo in uporabo TruScient lahko ogrozi njegovo varnost in učinkovitost.
Prepare sponges at least 15 minutes prior to use from components contained in the kit.
Gobici je treba s pomočjo ostalih sestavin, ki so v kompletu, pripraviti vsaj 15 minut pred uporabo.
The possibility of an immune response to the product should be evaluated in cases where an undesirable effect with immunological background is suspected.
V primerih suma, da so neželeni učinki imunološkega porekla, je treba oceniti možnost imunskega odgovora na zdravilo.
Type I bovine collagen
Goveji kolagen tipa I
PACKAGE LEAFLET FOR: TruScient 0.66 mg kit for implant for dogs
NAVODILO ZA UPORABO TruScient 0,66 mg komplet za implantacijo za pse
Use care to ensure that accurate volumes are used in reconstitution and application of the dibotermin alfa (rhBMP-2) solution to the sponge.
Zagotovite, da so uporabljene ustrezne količine pri rekonstituciji in nanašanju raztopine dibotermina alfa (rhBMP-2) na gobici.
During handling, avoid excessive fluid loss from the prepared sponges.
Pazite, da med ravnanjem s pripravljenimi gobicami iz njih ne izteče preveč tekočine.
After reconstitution, TruScient solution contains 0.2 mg/ml of dibotermin alfa (rhBMP-2).
Po rekonstituciji TruScient vsebuje 0,2 mg/ml dibotermina alfa (rhBMP-2).
Read the instructions for preparation and use below each time the veterinary medicinal product is used.
Pred vsako uporabo zdravila preberite navodila za pripravo in uporabo.
Failure to follow the product preparation instructions may compromise its safety and effectiveness.
Neupoštevanje navodil za pripravo lahko ogrozi varnost in učinkovitost zdravila.
Achieve definitive fracture reduction, fixation, and hemostasis prior to placement of the prepared sponge.
Pred implantacijo pripravljene gobice je treba doseči dokončno redukcijo zloma, fiksacijo in hemostazo.
One vial of lyophilisate contains 0.66 mg of dibotermin alfa (rhBMP-2)*
Ena viala z liofilizatom vsebuje 0,66 mg dibotermina alfa (rhBMP-2).
ABSORBABLE COLLAGEN SPONGE LABEL
NALEPKA ZA KOLAGENSKO GOBO
The maximum recommended dosage is the entire contents of a single TruScient kit for each dog (i.e., up to two 2.5 x 5 cm prepared TruScient sponges per dog).
Največji priporočeni odmerek je celotna vsebina enega kompleta za implantacijo za enega psa (t.j.
Discard any unused veterinary medicinal product.
Neuporabljeno zdravilo zavrzite.
The prepared sponge may be wrapped around the bone or placed up to the edges of a bone plate as the geometry of the fracture and fixation requires.
Glede na geometrijo zloma in fiksacijo lahko pripravljeno gobico ovijete okoli kosti ali jo namestite do robov ploščice.
Disinfect with alcohol the stoppers of the lyophilisate and the solvent vials.
Zamaške vial z liofilizatom in vehiklom razkužite z alkoholom.